Correlation Between Apellis Pharmaceuticals and Ionis Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Ionis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Ionis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Apellis Pharmaceuticals and Ionis Pharmaceuticals, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Ionis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Ionis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Ionis Pharmaceuticals.

Diversification Opportunities for Apellis Pharmaceuticals and Ionis Pharmaceuticals

0.79
  Correlation Coefficient

Poor diversification

The 3 months correlation between Apellis and Ionis is 0.79. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Ionis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ionis Pharmaceuticals and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Ionis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ionis Pharmaceuticals has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Ionis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Ionis Pharmaceuticals

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to generate 1.6 times more return on investment than Ionis Pharmaceuticals. However, Apellis Pharmaceuticals is 1.6 times more volatile than Ionis Pharmaceuticals. It trades about 0.24 of its potential returns per unit of risk. Ionis Pharmaceuticals is currently generating about -0.14 per unit of risk. If you would invest  2,771  in Apellis Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of  643.00  from holding Apellis Pharmaceuticals or generate 23.2% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Apellis Pharmaceuticals  vs.  Ionis Pharmaceuticals

 Performance 
       Timeline  
Apellis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Ionis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ionis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Apellis Pharmaceuticals and Ionis Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Apellis Pharmaceuticals and Ionis Pharmaceuticals

The main advantage of trading using opposite Apellis Pharmaceuticals and Ionis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Ionis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ionis Pharmaceuticals will offset losses from the drop in Ionis Pharmaceuticals' long position.
The idea behind Apellis Pharmaceuticals and Ionis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges